Stemline – About the Company

Stemline Therapeutics is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline’s development candidates include SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase 1/2 studies of advanced cancer patients.

SL-401 demonstrated single agent activity in multiple indications, including durable CRs in relapsed/refractory AML and relapsed/refractory BPDCN. In addition, SL-401 was well-tolerated and not toxic to the bone marrow. SL-401 is being advanced into pivotal Phase 2b programs in relapsed or refractory BPDCN and third-line AML.

Stemline’s second clinical candidate SL-701 has demonstrated single agent activity including durable CRs and PRs in adult patients with refractory/recurrent glioblastoma and pediatric patients with malignant glioma. This product is now ready to enter later stage trials in pediatric and adult patients with advanced brain cancer.

Research Reports